IRUZID PILLS 20MG/12.5MG
IRUZID PILLS 20MG/12.5MG - 30 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Active ingredient and dosage form
Iruzid - tablets:
1 tab. contains lisinopril dihydrate (in terms of lisinopril anhydrous) 10 and 20 mg; hydrochlorothiazide 12.5 and 20 mg; 30 pieces per pack.
Mechanism of action
Iruzid has an antihypertensive, diuretic effect.
Indications and usage
Arterial hypertension (in patients for whom combination therapy is indicated).
Contraindications
hypersensitivity to Iruzid, other ACE inhibitors and sulfonamide derivatives;
anuria;
severe renal insufficiency (Cl creatinine <30 ml / min.);
angioedema (including and in history with the use of ACE inhibitors);
hemodialysis using high-flow membranes;
hypercalcemia;
hyponatremia;
porphyria;
precoma;
hepatic coma;
severe diabetes;
age up to 18 years (efficacy and safety have not been established).
Pregnancy and Breastfeeding
The use of lisinopril during pregnancy is contraindicated. At establishment of pregnancy reception of Iruzida needs to be stopped as soon as possible. Acceptance of inhibitors in the II and III trimester of pregnancy has an adverse effect on the fetus (pronounced decrease in blood pressure, renal failure, hyperkalemia, cranial hypoplasia, fetal death are possible).Data on the negative effects of the drug on the fetus in the case of use during the first trimester is not. For newborns and infants who have undergone intrauterine effects of ACE inhibitors, it is recommended to monitor for the timely detection of pronounced reduction in blood pressure, oliguria, hyperkalemia.
For the period of treatment with Iruzid, breastfeeding should be canceled.
Adverse reactions
The most common side effects are dizziness, headache.
Other adverse events
Cardiovascular: marked reduction in blood pressure, chest pain; rarely - orthostatic hypotension, tachycardia, bradycardia, the appearance of symptoms of heart failure, impaired AV conduction, myocardial infarction.
On the part of the digestive tract: nausea, vomiting, abdominal pain, dry mouth, diarrhea, dyspepsia, anorexia, change in taste, pancreatitis, hepatitis (hepatocellular and cholestatic), jaundice.
On the part of the skin: urticaria, increased sweating, photosensitivity, pruritus, hair loss.
On the part of the nervous system: mood lability, impaired concentration, paresthesia, fatigue, drowsiness, jerky muscles of the limbs and lips; rarely - asthenic syndrome, confusion.
On the part of the respiratory system: dyspnea, bronchospasm, apnea.
On the part of the hemopoietic system: leukopenia, thrombocytopenia, neutropenia, agranulocytosis,anemia (decrease in hemoglobin, hematocrit, erythrocytopenia).
Allergic reactions: angioedema of the face, extremities, lips, tongue, epiglottis and / or larynx (see "Special Instructions"), skin rashes, itching, fever, vasculitis, positive reactions to antinuclear antibodies, increased ESR, eosinophilia.
From the genitourinary system: uremia, oliguria / anuria, impaired renal function, acute renal failure, reduced potency.
Dosage and administration
Inside 1 tab. Iruzid10 mg + 12.5 mg or 20 mg + 12.5 mg once a day. Sometimes, if necessary, the dose can be increased to Iruzid 20 mg + 25 mg 1 time per day.
Special notes
During the period of treatment is not recommended to drink alcohol, because alcohol enhances the hypotensive effect of the drug.
Storage conditions
In the dark place at a temperature of no higher than 25 ° C.